Reutericin
Reutericin is a Class II bacteriocin produced by select strains of Lactobacillus reuteri with antimicrobial activity against Gram-positive pathogens. It represents one of several antimicrobial mechanisms employed by L. reuteri, a widely used probiotic species, and is being investigated for microbiome defense and food safety applications.
Reutericin is a bacteriocin — a ribosomally synthesized antimicrobial peptide — produced by certain strains of Lactobacillus reuteri (reclassified as Limosilactobacillus reuteri in 2020). Multiple reutericin variants have been identified, including reutericin 6, reutericin A, and a circular bacteriocin (reutericin produced by L. reuteri LA6), each with distinct structural features and spectra of activity.
Overview
Lactobacillus reuteri is among the most extensively studied probiotic species, with a well-documented presence in the gastrointestinal tract of humans and other vertebrates. The species deploys multiple antimicrobial strategies for ecological competition: organic acid production (lactic and acetic acid), reuterin (3-hydroxypropionaldehyde, a non-peptide antimicrobial produced from glycerol by glycerol dehydratase), and bacteriocins including reutericin.
The distinction between reutericin (peptide bacteriocin) and reuterin (small-molecule antimicrobial) is important. Reuterin is a three-carbon aldehyde produced from glycerol via the pdu (propanediol utilization) operon-encoded glycerol dehydratase. It is not a peptide and acts through broad-spectrum protein crosslinking and oxidative damage. Reutericin, by contrast, is a gene-encoded peptide with receptor-mediated killing activity and a narrower spectrum.
Several reutericin variants have been characterized:
Reutericin 6: Originally isolated from L. reuteri LA6 by Kabuki et al. (1997), this is a circular (head-to-tail cyclized) bacteriocin classified as Class IIc. Circular bacteriocins are characterized by their enhanced thermostability and protease resistance relative to linear counterparts. Reutericin 6 consists of 58 amino acids with a molecular mass of approximately 5.6 kDa and is active against Lactobacillus delbrueckii, L. helveticus, and other closely related LAB species Kabuki et al. (1997).
Reutericin A: A heat-stable, protease-sensitive bacteriocin produced by L. reuteri LA6 with activity against Listeria monocytogenes and other Gram-positive pathogens. Its structural classification places it among Class IIa (pediocin-like) bacteriocins containing the conserved YGNGV/L N-terminal motif that characterizes anti-listerial bacteriocins.
Other L. reuteri bacteriocins: Additional antimicrobial peptides have been identified from various L. reuteri strains through genome mining, including potential lantibiotics and two-peptide bacteriocins, reflecting the genomic diversity of this species.
Mechanism of Action
The antimicrobial mechanism of reutericin involves membrane disruption through several coordinated steps:
- Target cell recognition: Reutericin interacts with the target cell membrane, likely through electrostatic attraction between the cationic peptide and anionic phospholipids in the bacterial membrane. Specific receptor molecules (e.g., mannose PTS components for Class IIa bacteriocins) may also mediate initial binding, conferring spectrum specificity.
- Membrane insertion: Following binding, the amphipathic helical structure of reutericin inserts into the lipid bilayer. Circular bacteriocins such as reutericin 6 are particularly effective at membrane insertion due to their compact, stable fold and defined hydrophobic surface.
- Pore formation and ion leakage: Reutericin oligomerizes in the membrane to form transient pores, causing efflux of potassium ions, dissipation of the proton motive force (PMF), and depletion of intracellular ATP. The collapse of PMF halts energy-dependent processes including nutrient uptake and biosynthesis Gálvez et al. (2007).
- Cell death: The combined effects of ion leakage, PMF dissipation, and ATP depletion lead to rapid bactericidal killing. Unlike bacteriolytic enzymes, bacteriocins do not typically lyse target cells — death occurs through energy depletion rather than cell wall destruction.
- Producer self-immunity: L. reuteri strains producing reutericin co-express dedicated immunity proteins that protect the producer from its own bacteriocin. These immunity proteins are typically small membrane-associated peptides that interfere with pore formation or expel the bacteriocin from the producer cell membrane.
Reconstitution Calculator
Reconstitution Calculator
Calculate your peptide dosing
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Spectrum of Activity
Reutericin variants display activity primarily against Gram-positive bacteria. The spectrum of reutericin 6 includes Lactobacillus delbrueckii, L. helveticus, L. acidophilus, and other LAB species — consistent with its ecological role in intraspecific and interspecific competition within the LAB-dominated gut and food fermentation niches. Reutericin A and related pediocin-like variants from L. reuteri exhibit broader activity that includes Listeria monocytogenes, certain Enterococcus species, and Clostridium strains Toba et al. (1991).
Gram-negative bacteria are generally resistant to reutericins due to the outer membrane barrier, which prevents peptide access to the cytoplasmic membrane. However, outer membrane-permeabilizing agents (EDTA, lactoferrin, organic acids) can sensitize Gram-negative organisms to bacteriocin-mediated killing, a principle exploited in hurdle technology for food preservation.
Comparison with Reuterin
The antimicrobial repertoire of L. reuteri is uniquely diverse among probiotic species, combining both peptide (reutericin) and non-peptide (reuterin) antimicrobials:
| Property | Reutericin | Reuterin |
|---|---|---|
| Chemical nature | Ribosomally synthesized peptide | 3-hydroxypropionaldehyde (3-HPA) |
| Molecular weight | ~5 kDa | 74 Da |
| Biosynthesis | Bacteriocin gene cluster | Glycerol dehydratase (pdu operon) |
| Substrate required | None (constitutive) | Glycerol |
| Spectrum | Primarily Gram-positive | Broad-spectrum (Gram+, Gram-, fungi, protozoa) |
| Mechanism | Membrane pore formation | Protein crosslinking, thiol oxidation |
| Resistance | Receptor modification | Aldehyde reductase expression |
| Stability | Heat-stable (circular variants) | Unstable; polymerizes in aqueous solution |
This dual antimicrobial strategy — narrow-spectrum bacteriocin plus broad-spectrum aldehyde — provides L. reuteri with ecological flexibility: reutericin for targeted elimination of competing LAB, and reuterin for broad-spectrum defense against diverse pathogens when glycerol is available Spinler et al. (2008).
Food Safety Applications
Reutericin-producing L. reuteri strains are being investigated as protective cultures for food preservation:
- Biopreservation of fermented foods: Addition of reutericin-producing L. reuteri to fermented dairy, meat, and vegetable products provides anti-listerial activity without affecting the desired fermentation microbiota.
- Active packaging: Incorporation of reutericin into edible films and coatings for inhibition of surface-contaminating pathogens on ready-to-eat foods.
- Synergistic hurdle approaches: Combination of reutericin with organic acids, modified atmosphere, and refrigeration creates multiple antimicrobial barriers that extend shelf life while reducing chemical preservative use Gálvez et al. (2007).
Genomic and Strain Diversity
Genome mining of L. reuteri strains from diverse hosts and environments has revealed substantial bacteriocin gene cluster diversity. Not all L. reuteri strains produce bacteriocins — this trait is strain-specific and often associated with genomic islands acquired through horizontal gene transfer. The L. reuteri species can be divided into host-adapted lineages (human, rodent, swine, poultry), and bacteriocin gene content varies between lineages, suggesting that antimicrobial peptide repertoires are shaped by the competitive landscape of specific host niches Oh et al. (2010).
Role in Probiotic Efficacy
Bacteriocin production is increasingly recognized as a mechanistic basis for probiotic effects, moving beyond the "black box" of undefined probiotic mechanisms. For L. reuteri, several clinical benefits may be attributable at least in part to reutericin and reuterin production:
- Infantile colic: L. reuteri DSM 17938 is the best-evidenced probiotic for reducing crying time in breastfed infants with colic. While the mechanism is multifactorial, antimicrobial activity against gas-producing coliforms and clostridia may reduce intestinal gas and distension Savino et al. (2007).
- Helicobacter pylori suppression: Multiple trials show L. reuteri supplementation reduces H. pylori load, though eradication rates are modest. Reuterin, rather than reutericin, is likely the primary effector against this Gram-negative organism.
- Oral health: L. reuteri strains producing bacteriocins reduce counts of Streptococcus mutans and periodontal pathogens. Probiotic lozenges containing L. reuteri ATCC PTA 5289 and DSM 17938 have demonstrated efficacy in reducing gingivitis and plaque indices Teughels et al. (2013).
Safety Profile
Reutericin inherits the favorable safety profile associated with L. reuteri and LAB bacteriocins generally:
- GRAS status of producer: L. reuteri has GRAS status and Qualified Presumption of Safety (QPS) status in the EU. Multiple strains (DSM 17938, ATCC PTA 5289, ATCC 55730) have been used in clinical trials involving neonates, infants, children, and adults with no serious adverse events attributable to the probiotic.
- Proteolytic inactivation: Like most Class II bacteriocins, reutericin is susceptible to degradation by gastrointestinal proteases (pepsin, trypsin, chymotrypsin), limiting systemic exposure and confining activity to the luminal environment.
- No cytotoxicity to eukaryotic cells: At concentrations relevant to antimicrobial activity, bacteriocins from LAB species do not damage mammalian cell membranes. The selectivity arises from the fundamental difference between prokaryotic (anionic phospholipid-rich) and eukaryotic (cholesterol-stabilized, zwitterionic phospholipid) membranes.
- Narrow spectrum: The primarily anti-LAB spectrum of reutericin 6 limits collateral damage to the commensal microbiota. However, broader-spectrum variants (reutericin A) could potentially affect beneficial lactobacilli if delivered at high concentrations.
- No known allergenicity: No allergic or hypersensitivity reactions have been reported in association with bacteriocin-producing L. reuteri strains in clinical or food-use settings.
Pharmacokinetic Profile
- Half-life
- Variable; sensitive to proteolytic degradation in vivo
Quick Start
- Route
- Oral (via probiotic delivery), topical (food preservation research)
Molecular Structure
- Formula
- Varies by variant
- CAS
- Not assigned (research compound)
Research Protocols
oral
Administered via oral.
topical
Administered via topical.
Interactions
Peptide Interactions
The antimicrobial repertoire of L. reuteri is uniquely diverse among probiotic species, combining both peptide (reutericin) and non-peptide (reuterin) antimicrobials: | Property | Reutericin | Reuterin | |----------|-----------|---------| | Chemical nature | Ribosomally synthesized peptide | 3-hy...
Quality Indicators
What to look for
- Well-established safety profile
- Multiple peer-reviewed studies available
- GRAS (Generally Recognized As Safe) status
Red flags
- Significant side effect risk noted
Frequently Asked Questions
References (14)
- [14]
- [11]Zhao Q et al — Genome mining reveals novel bacteriocin gene clusters in Limosilactobacillus reuteri (2023)
- [12]Gaspar C et al — Antimicrobial and immunomodulatory properties of Limosilactobacillus reuteri (2022)
- [13]Bitschar K et al — Circular bacteriocins from human gut commensals: biosynthesis, structure, and ecological function Nat Chem Biol (2023)
- [2]Toba T, Samant SK, Yoshioka E, Itoh T Reutericin 6, a new bacteriocin produced by Lactobacillus reuteri (1991)
- [1]Kabuki T, Saito T, Kawai Y, et al Production of a circular bacteriocin (reutericin 6) by Lactobacillus reuteri (1997)
- [3]Gálvez A, Abriouel H, López RL, Ben Omar N Bacteriocin-based strategies for food biopreservation Int J Food Microbiol (2007)
- [5]Savino F, Pelle E, Palumeri E, et al *Lactobacillus reuteri* (American Type Culture Collection Strain 55730) versus simethicone in the treatment of infantile colic Lactobacillus reuteri (2007)
- [7]Oh PL, Benson AK, Peterson DA, et al Diversification of the gut symbiont Lactobacillus reuteri (2010)
- [8]
- [9]Perez RH, Zendo T, Sonomoto K Novel bacteriocins from lactic acid bacteria (LAB): various structures and applications Microb Cell Fact (2014)
- [10]Walter J Ecological role of lactobacilli in the gastrointestinal tract Appl Environ Microbiol (2008)
- [6]Teughels W, Durukan A, Ozcelik O, et al Clinical and microbiological effects of Lactobacillus reuteri (2013)
- [4]Spinler JK, Taweechotipatr M, Rognerud CL, et al Human-derived probiotic Lactobacillus reuteri (2008)
Retinalamin
Retinalamin is a complex of polypeptides isolated from the retina of cattle, studied as a bioregulatory agent for retinal neuroprotection, age-related macular degeneration, diabetic retinopathy, retinitis pigmentosa, and glaucoma in Russian clinical practice.
Revilab SL 01
Revilab SL 01 is a sublingual multi-peptide bioregulator formulation from the Revilab product line, developed by Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology. It combines short bioregulatory peptides targeting multiple organ systems for anti-aging applications.